INAMRINONE

Course overview

INAMRINONE IS A MEDICATION USED IN THE SHORT-TERM MANAGEMENT AND TREATMENT OF CONGESTIVE HEART FAILURE. IT IS A PHOSPHODIESTERASE-III INHIBITOR, WHICH INCREASES CARDIAC INOTROPY. IT IS PRESCRIBED FOR SHORT-TERM MANAGEMENT TO RELIEVE SYMPTOMS OF CHF, SUCH AS FATIGUE, WEAKNESS, EDEMA, DYSPNEA, ORTHOPNEA, AND PAROXYSMAL NOCTURNAL DYSPNEA. THIS ACTIVITY OUTLINES THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR THIS DRUG AS A VALUABLE AGENT IN MANAGING ACUTE CONGESTIVE HEART FAILURE. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., OFF-LABEL USES, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, RELEVANT INTERACTIONS) PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE TREATMENT OF PATIENTS WITH CONGESTIVE HEART FAILURE AND RELATED CONDITIONS.